Virginia Oncology Associates

Jun 27, 2024 | jamanetwork.com | Virginia Oncology Associates |Amanda Blackford |Kristy K Broman

Geographic Disparities in Head and Neck Cancer Mortality and Place of Death Despite advances in management, mortality gains for patients with head and neck cancer (HNC) may not be equally distributed across geographic regions with varying levels of vaccine and screening uptake, risk factor reduction, and access to treatment and end-of-life (EOL) care services.1 This cross-sectional study evaluated disparities in age-adjusted mortality rates (AAMRs) and place of death for individuals with HNC...

Apr 4, 2024 | europeanurology.com | Florian Roghmann |Elena Fernandez |Elena Fernández |Mark Fleming |Virginia Oncology Associates

It has previously been estimated that FGFR3 gene mutation or fusion occurs in approximately 20% of patients with advanced lower tract urothelial cancer (LTUC) and up to 40–50% of patients with advanced upper tract urothelial cancer (UTUC) [1Ross J.S. Wang K. Khaira D. et al. Comprehensive genomic profiling of 295 cases of clinically advanced urothelial carcinoma of the urinary bladder reveals a high frequency of clinically relevant genomic alterations. , 2Necchi A. Madison R. Pal S.K. et al.

Apr 6, 2023 | thelancet.com | David Chang |Virginia Oncology Associates |Tim Larson |Allen L. Cohn

SummaryBackgroundAnti-programmed cell death protein 1 antibodies plus multikinase inhibitors have shown encouraging activity in several tumour types, including colorectal cancer. This study assessed regorafenib plus nivolumab in patients with microsatellite stable/mismatch repair-proficient metastatic colorectal cancer.